Obesity does not always behave like a one-treatment disease.
Obesity is chronic and adaptive. Different treatment mechanisms may sometimes be used together or in sequence.
Acts mainly through appetite regulation and satiety, with important metabolic effects. Molecule, formulation, dose, duration and tolerability all matter.
Provides a temporary gastric intervention that supports earlier fullness, portion control and structured behaviour change without surgery.
The question is rarely just “Can I combine them?”
A less-invasive pathway may be appropriate for some patients, but treatment intensity should still match obesity severity and metabolic disease burden.
That makes treatment sequencing important. The issue is not simply starting a medicine, but deciding what role it should play in the full treatment journey.
Maintenance is one of the most important clinical questions. Temporary treatment should be paired with a long-term plan for appetite, behaviour, metabolic health and weight recurrence.
The aim is not to add treatment for the sake of treatment. The question is whether another mechanism meaningfully improves response or durability.
What did we actually study?
A randomized double-blind study at Mohak compared swallow balloon therapy with and without oral semaglutide.
Study-specific group outcomes. They do not predict an individual patient’s result.
Oral semaglutide was used in a stepped-dose regimen in this study. Nausea and vomiting were among the common early adverse events. See the reference section for the full citation.
“The study gives us an answer. But it also gives us better questions.”— Dr Mohit Bhandari
It may not only be about which treatments are used. Timing may matter too.
Concurrent therapy
GLP-1 therapy and balloon treatment overlap. The research question is whether any gain in efficacy justifies the additional gastrointestinal burden.
Adjunctive therapy
Medication is introduced during balloon therapy and may continue after the balloon phase, aiming to extend treatment momentum and support maintenance.
Sequential therapy
The balloon is used first; GLP-1 therapy follows later. This may be particularly relevant to the question of post-balloon weight maintenance.
What benefit are we actually trying to create?
The objective is not simply to add treatments. It is to improve the quality, tolerability and durability of the response.
Treatment should feel like a plan, not a sequence of failures.
A patient may enter, leave or move between these stages differently. This is not a prescription; it is a framework for discussing multimodal care.
Weight history, BMI, metabolic disease, prior treatment and preferences.
Medical, balloon, surgery or another pathway based on disease severity.
Nutrition, activity, behaviour and regular medical follow-up.
Weight, symptoms, metabolic health, tolerability and adherence.
Continue, sequence, combine, step down or discuss surgery.
Plan for weight recurrence rather than treating follow-up as optional.
Efficacy is only half the equation.
Both GLP-1 therapy and gastric balloon treatment can produce gastrointestinal symptoms. The clinical question is whether added benefit is worth the added treatment burden for the individual patient.
Good research should create better questions, not bigger claims.
What the evidence currently suggests
- The Mohak randomized study found greater short-term %TWL with swallow balloon + oral semaglutide than balloon alone.
- Newer prospective evidence suggests adjunctive semaglutide may improve weight-loss durability after balloon removal.
- Emerging observational evidence suggests sequential balloon → GLP-1 therapy may be worth further study.
What remains uncertain
- Which patient phenotype benefits most.
- The ideal timing and duration of GLP-1 therapy.
- Whether concurrent or sequential treatment is superior.
- Long-term outcomes beyond current follow-up periods.
- Cost-effectiveness and comparison with newer incretin therapies.
Three patients can need three different strategies.
Illustrative examples only.
Good medical response, low residual disease burden
A patient has meaningful weight loss, good tolerability and improved metabolic health.
Partial response, strong appetite and post-balloon maintenance concern
A patient wants a less-invasive pathway but needs more support than one modality alone has provided.
Severe obesity with major metabolic disease
Diabetes, sleep apnea or other disease burden remains significant despite repeated attempts.
The real question is: what should happen next?
What has the patient already achieved?
Weight matters, but so do diabetes control, fatty liver, sleep apnea, blood pressure, mobility and quality of life.
How much clinically important obesity still remains?
A good early response does not automatically mean the residual metabolic or mechanical disease burden is small.
Is the current strategy sustainable?
Effectiveness, tolerability, adherence, cost, access and patient preference all matter in chronic obesity care.
Would another mechanism add real value?
This is where a balloon, pharmacotherapy or structured sequencing may deserve discussion.
Is escalation to metabolic surgery more appropriate?
Less-invasive therapies should not be added indefinitely when the severity of obesity or metabolic disease warrants a different level of intervention.
The future is not medicine versus balloon versus surgery.
These are different therapeutic tools. The challenge is to select, sequence and escalate treatment according to disease severity and response — with long-term follow-up throughout.
“Treatment intensity should match disease severity. The future of obesity care will be defined by better patient selection, better sequencing and better long-term maintenance.”
The aim is to match treatment intensity to disease severity, previous response and long-term goals.
Frequently asked questions
Can GLP-1 therapy and a swallowable balloon be used together?
They have been studied together, including in a randomized double-blind study conducted at Mohak using oral semaglutide with swallow balloon therapy. That does not mean the combination is automatically appropriate for everyone. The decision depends on obesity severity, medical history, the exact medication and dose, expected benefit, treatment tolerance and the overall plan for maintenance.
Does combining the two mean twice the weight loss?
No. Weight loss is not additive in a simple mathematical way. Published studies report average outcomes for groups of participants under specific protocols. An individual patient may respond differently, and no study result can be used as a personal guarantee.
Why would a doctor consider using both treatments?
The rationale is that the two approaches act differently. GLP-1-based therapy primarily influences appetite regulation and satiety, while a swallowable balloon provides a temporary gastric-volume effect that can support earlier fullness and portion control. In some patients, combining or sequencing these mechanisms may be worth discussing when a single approach is not achieving the desired clinical response.
Should the medicine be started with the balloon or after it?
There is no single schedule that is right for every patient. Research is exploring concurrent use, medication introduced during balloon therapy, and sequential treatment after the balloon phase. The timing may affect both efficacy and tolerability, which is why the sequence should be planned clinically rather than copied from someone else's treatment.
What side effects or tolerability issues should patients understand?
Both GLP-1-based treatments and gastric balloons can cause gastrointestinal symptoms such as nausea, vomiting, fullness or abdominal discomfort. Using more than one treatment does not remove those risks and may increase the treatment burden for some people. Monitoring, dose planning, hydration, nutrition and timely clinical review are therefore important parts of the strategy.
Is this a way to avoid bariatric surgery?
Not necessarily. A non-surgical strategy may be appropriate for some patients, but it should not be used simply to postpone surgery when obesity severity or metabolic disease suggests that bariatric or metabolic surgery deserves serious consideration. Treatment intensity should match disease severity rather than fear of a particular procedure.
Who may need an earlier bariatric or metabolic surgery discussion?
Patients with more severe obesity, significant type 2 diabetes, sleep apnea, fatty liver disease, substantial mobility burden, repeated weight recurrence, or an inadequate response to less-invasive care may benefit from discussing surgery earlier in the treatment pathway. A consultation does not commit a patient to surgery; it helps clarify whether surgery belongs among the realistic options.
What if my weight has plateaued on GLP-1 treatment?
A plateau does not automatically mean the medicine has failed. It may reflect the body's adaptation to weight loss, a maintenance phase, or an incomplete response that needs reassessment. The next step should be based on how much weight has been lost, what obesity-related conditions remain, treatment tolerance and whether another medical, device-based or surgical strategy should be discussed.
Dr Mohit Bhandari
Bariatric, metabolic and robotic surgery specialist.
View Dr Mohit Bhandari’s profile →References
- Mathur W, Kosta S, Reddy M, Galvao Neto M, Bhandari M. Effect of Swallow Balloon Therapy with the Combination of Semaglutide Oral Formulation: a Randomised Double-Blind Single-Centre Study. Obes Surg. 2024;34(1):198–205. DOI: 10.1007/s11695-023-06975-8. PubMed
- Barakat KE, et al. Adjunctive Semaglutide in Patients Undergoing Intragastric Balloon for Weight Loss: 12-Month Prospective Comparative Study. Obes Surg. 2025;35(12):5398–5409. DOI: 10.1007/s11695-025-08368-5. PubMed
- Sequential Intragastric Balloon Followed By GLP-1 Receptor Agonist Therapy in Obesity: A Comparative Study of 12-Month Weight Loss Outcomes. 2026. PubMed
Evidence note: these studies use different designs, gastric-balloon platforms and semaglutide regimens. Results should be interpreted within each study context rather than treated as directly interchangeable.